Filing Details

Accession Number:
0001209191-20-024250
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-13 19:16:20
Reporting Period:
2020-04-09
Accepted Time:
2020-04-13 19:16:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595893 Turning Point Therapeutics Inc. TPTX Pharmaceutical Preparations (2834) 463826166
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1772259 Jean Jingrong Cui C/O Turning Point Therapeutics, Inc.
10628 Science Center Drive, Ste. 200
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-04-09 5,982 $46.81 720,609 No 4 S Indirect By spouse
Common Stock Disposition 2020-04-09 3,626 $47.82 716,983 No 4 S Indirect By spouse
Common Stock Disposition 2020-04-09 1,892 $48.75 715,091 No 4 S Indirect By spouse
Common Stock Disposition 2020-04-13 200 $48.44 714,891 No 4 S Indirect By spouse
Common Stock Disposition 2020-04-13 200 $49.87 714,691 No 4 S Indirect By spouse
Common Stock Disposition 2020-04-13 308 $51.22 714,383 No 4 S Indirect By spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By spouse
No 4 S Indirect By spouse
No 4 S Indirect By spouse
No 4 S Indirect By spouse
No 4 S Indirect By spouse
No 4 S Indirect By spouse
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,001,298 Direct
Common Stock 300,000 Indirect By The Jean Cui 2020 GRAT
Footnotes
  1. Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
  2. The weighted average sale price for the transaction reported was $46.81, and the range of prices were between $46.31 and $47.275. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. The weighted average sale price for the transaction reported was $47.82, and the range of prices were between $47.32 and $48.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  4. The weighted average sale price for the transaction reported was $48.75, and the range of prices were between $48.35 and $49.145. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  5. The weighted average sale price for the transaction reported was $48.44, and the range of prices were between $48.405 and $48.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  6. The weighted average sale price for the transaction reported was $49.87, and the range of prices were between $49.65 and $50.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  7. The weighted average sale price for the transaction reported was $51.22, and the range of prices were between $51.135 and $51.3275. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.